Mild nausea after a dose increase may improve, while repeated vomiting, dehydration, severe pain, or the inability to pass stool or gas needs faster medical review
CBO estimates that it would cost $1.5 billion to the federal government in the first year alone, rising to $6.1 billion in 2034 (see figure 1)
People who cease taking GLP-1 obesity drugs, which include semaglutide (Wegovy) and tirzepatide (Zepbound), typically regain an average of nearly a pound a month, ultimately gaining back all the weight they lost within two years, according to a review of 37 earlier studies
The extent to which these subjective changes translate into sustained behavioural change and improved clinical outcomes requires further investigation through rigorous clinical trials
With semaglutide, most patients notice appetite suppression within the first few weeks, with measurable weight loss beginning by weeks 4 to 8